Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22006023 | 0.76 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20128810 | 0.75 | — | — | |
| SCHEMBL13656337 | 0.75 | ALDH1A1 (0.49) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2734116 | 0.75 | ALDH1A1 (0.49) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9541684 | 0.75 | HRH3 (0.57) | KDM4EALDH1A1KMT2APSMB1PSMB5 | |
| SCHEMBL9542084 | 0.75 | HRH3 (0.57) | KDM4EALDH1A1KMT2APSMB1PSMB5 | |
| SCHEMBL9544441 | 0.75 | HRH3 (0.57) | KDM4EALDH1A1KMT2APSMB1PSMB5 | |
| SCHEMBL824037 | 0.73 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL24059343 | 0.73 | HRH3 (0.60) | KDM4ESMN1; SMN2PSMB1PSMB5PSMB2 | |
| SCHEMBL10914988 | 0.73 | HRH3 (0.52) | KDM4EALDH1A1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885ALDH1A1 2896/4885SMN1; SMN2 1794/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | KDM4E 3116/4885ALDH1A1 2833/4885SMN1; SMN2 2113/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885ALDH1A1 2896/4885SMN1; SMN2 1794/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | KDM4E 1787/4885ALDH1A1 2935/4885SMN1; SMN2 1543/4885 |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | KDM4E 3237/4885ALDH1A1 3692/4885SMN1; SMN2 1141/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | KDM4E 1212/4885ALDH1A1 4249/4885SMN1; SMN2 787/4885 |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | KDM4E 2143/4885ALDH1A1 3773/4885SMN1; SMN2 588/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | KDM4E 1787/4885ALDH1A1 2935/4885SMN1; SMN2 1543/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | KDM4E 2704/4885ALDH1A1 2567/4885SMN1; SMN2 269/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | KDM4E 1254/4885ALDH1A1 4031/4885SMN1; SMN2 4046/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | KDM4E 1205/4885ALDH1A1 3688/4885SMN1; SMN2 881/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | KDM4E 1438/4885ALDH1A1 2301/4885SMN1; SMN2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.